Psoriatic Arthritis | Unmet Need | US/EU | 2023
TNF-alpha inhibitors continue to be the preferred choice to treat psoriatic arthritis (PsA) following failure on conventional DMARDs. However, other biologics such as IL-17 inhibitors (e.g., Cosentyx, Taltz), the IL-12/23 inhibitor Stelara, IL-23 inhibitors (e.g., Tremfya), and oral therapies (e.g., Otezla, Xeljanz) have begun to chip away at the TNF-alpha inhibitors’ patient share. Understanding the underlying unmet need in the treatment of PsA, as well as the factors that can differentiate products from one another, can determine an agent’s success in this competitive space. This report presents the key unmet needs in the treatment of PsA and provides the tools to make strategic decisions and assessments pertaining to this therapy market.
QUESTIONS ANSWERED
- How do current therapies perform on key treatment drivers and goals for PsA?
- Which drug attributes are key influencers, which have limited impact, and which are the hidden opportunities in PsA?
- What are the prevailing areas of unmet need and opportunity in the PsA market?
- What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new PsA drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 34 European rheumatologists and dermatologists fielded in February 2023
Key companies: AbbVie, Amgen, Pfizer, Janssen, Novartis, Eli Lilly
Key drugs: Humira, Cosentyx, Taltz, Stelara, Tremfya, Otezla, Xeljanz
